

The Evolution of SARS-CoV-2 Delta and Omicron Variants: Transmission Dynamics and Public Health Response

Prisha Sakhare
prisha.sakhare6@gmail.com

ABSTRACT

The emergence of the Delta (B.1.617.2) and Omicron (B.1.1.529) variants of SARS-CoV-2 fundamentally altered the global trajectory of the COVID-19 pandemic, each introducing distinct epidemiological challenges that tested the limits of existing public health frameworks. Delta, which achieved global dominance by mid-2021, was characterised by high viral loads, a shortened serial interval, and markedly increased rates of hospitalisation and mortality, particularly among unvaccinated populations. Omicron, first identified in late November 2021, demonstrated even greater transmissibility alongside a remarkable capacity to evade prior immunity acquired through vaccination or earlier infection. Although Omicron was associated with comparatively milder clinical outcomes in vaccinated individuals, its extraordinary rate of spread produced substantial healthcare system strain across the globe. Both variants exposed critical vulnerabilities in pandemic preparedness infrastructure, including gaps in genomic surveillance, inequitable vaccine distribution, and the inadequacy of static, single-intervention public health approaches. Vaccination campaigns, booster programmes, and non-pharmaceutical interventions required repeated adaptation in response to the shifting characteristics of each variant. Existing literature consistently highlights that high transmissibility alone, even in the absence of proportionally severe disease, is sufficient to overwhelm healthcare systems and necessitate systemic policy reform. Collectively, the evidence underscores the need for adaptive policy frameworks, sustained genomic surveillance capacity, and equitable global access to vaccines and therapeutics in preparing for future variants of concern.

INTRODUCTION

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) is the virus responsible for causing the COVID-19 epidemic in 2019. It is a highly infectious virus that primarily affects the respiratory system and belongs to the coronavirus family, a group of viruses capable of infecting both humans and animals. SARS-CoV-2 spreads mainly from person to person through respiratory droplets released during coughing, sneezing, or talking. Less commonly, it may also spread through contact with contaminated

surfaces (Roy, 2024; World Health Organization, n.d.; Kumar et al., 2022).

As SARS-CoV-2 spread extensively across the globe, numerous variants emerged. Among these, the Delta and Omicron variants became especially notable because of their high transmissibility and widespread international spread (MD Anderson Cancer Center, 2021). Delta was associated with increased disease severity and rapid global dissemination, while Omicron and its sublineages demonstrated an even greater capacity for transmission, allowing them to quickly become dominant in many regions (Ada Health, n.d.). The continued emergence of these variants has substantially altered the transmission dynamics of SARS-CoV-2 by influencing infection rates, reinfection patterns, and, in some cases, the effectiveness of prior immunity from vaccination or earlier infection. As a result, the evolution of SARS-CoV-2 variants has underscored the importance of ongoing genomic surveillance, flexible public health responses, and continued adaptation of prevention and control strategies (Fisman & Tuite, 2021).

In contrast to Omicron, the Delta variant emerged earlier in the pandemic and was associated with more severe clinical outcomes than many previous strains. Before the rise of Omicron, Delta was a major driver of global infection waves and contributed substantially to hospitalizations and deaths worldwide. Due to its high transmissibility and greater severity, the Delta variant placed considerable strain on healthcare systems around the world (He et al., 2022). This review is drawn from existing literature and surveillance data to critically examine and interpret the public health responses to the Delta and Omicron variants of SARS-CoV-2.




Figure 1: Schematic Comparison of Delta and Omicron Variant Characteristics

The Concept of Public Health Strategies

Public health strategies are essential for monitoring, preventing, and controlling the spread of infectious diseases. Their importance became especially clear during the COVID-19 pandemic, as SARS-CoV-2 spread rapidly across populations and continued to evolve into new variants with differing transmissibility and virulence. In the setting of a novel and highly contagious pathogen, public health measures were critical not only for limiting transmission, but also for slowing epidemic growth, protecting vulnerable populations, and reducing the burden on healthcare systems. Without effective public health intervention, rapid surges in infection could lead to widespread morbidity and mortality while overwhelming hospitals and public health infrastructure.

During the COVID-19 pandemic, key public health strategies included non-pharmaceutical interventions such as social distancing, quarantine, travel restrictions, mask use, and contact tracing. These approaches were particularly important before vaccines and targeted treatments became widely available, as they helped reduce person-to-person spread and delay peaks in infection. Research has shown that such measures are most effective when implemented early, consistently, and in combination. In addition to these interventions, clear public communication, robust surveillance systems, testing capacity, and healthcare preparedness were essential components of an effective response. Because SARS-CoV-2 continued to evolve, public health strategies had to remain flexible and adaptive in order to respond to the changing transmissibility, severity, and immune-evasive characteristics of emerging variants. As a result, public health measures played a central role in shaping the course and outcomes of the COVID-19 pandemic (World Health Organization, n.d.).




Figure 2: Delta and Omicron Variant Case Trajectories Over Time

DELTA VIRUS

The Delta variant (B.1.617.2) of SARS-CoV-2 is a highly transmissible variant of concern that first emerged in late 2020 in India before rapidly achieving global dominance. It is characterised by key mutations in the spike (S) protein, particularly within the receptor-binding domain (RBD) of the S1 subunit, which is responsible for binding to human ACE2 receptors. Mutations such as L452R and P681R were instrumental in increasing viral entry efficiency and enhancing transmission. These molecular changes allowed Delta to outcompete earlier strains and drive successive waves of infection across the world (Roy, 2024; Kumar et al., 2022).

Clinically, Delta was associated with greater disease severity than prior variants, with studies indicating higher rates of hospitalization and ICU admission among unvaccinated individuals compared to those infected with earlier strains (Fisman & Tuite, 2021). The variant's propensity for severe lower respiratory tract disease, including viral pneumonia, contributed significantly to excess mortality, particularly in countries with limited healthcare infrastructure or low vaccination rates. In Germany, for example, mortality linked to Delta infection ultimately exceeded that of HIV during comparable time periods, illustrating the magnitude of its population-level impact (He et al., 2022).

Understanding Global Transmission Patterns of Delta Virus

The global transmission patterns of the Delta variant were defined by its rapid international spread and exceptional infectivity. After initial detection in India, Delta spread to over 160 countries within months, becoming the dominant global strain by mid-2021 and driving major infection waves across Asia, Europe, and North America (He et al., 2022). Its success was largely attributable to significantly higher viral loads compared to earlier strains, which increased the likelihood of transmission even during brief or incidental exposures and contributed to rapid community spread.

A key feature of Delta's transmission profile was its accelerated kinetics at both individual and population levels. The variant demonstrated a shorter serial interval and incubation period, meaning infected individuals became infectious sooner and transmitted the virus more rapidly—often before symptom onset. According to He et al. (2022), Delta took approximately 56 days to become dominant across 12 major locations and 70 days across 36 locations globally, reflecting a consistent and rapid pattern of competitive displacement. This shortened transmission interval rendered conventional containment strategies such as contact tracing significantly less effective, as a substantial proportion of onward transmission occurred prior to case identification.

Delta's transmission was also highly heterogeneous at the population level. Certain individuals and environments such as crowded indoor spaces with poor ventilation functioned as superspreading hubs that amplified transmission across communities. In the United States alone, infections tripled within a single month during 2021, with daily case counts rising from approximately 13,000 to over 56,000, underscoring the variant's capacity for rapid national spread (Roy, 2024). Globally, epidemiological modelling and

genomic surveillance data from Murray et al. (2024) confirmed that Delta's transmission characteristics were fundamentally distinct from prior variants, necessitating revised epidemiological models to understand and predict outbreak patterns.

Furthermore, Delta demonstrated the ability to sustain transmission even within partially vaccinated populations. While vaccination substantially reduced severe disease and to a lesser extent lowered transmission, it did not fully prevent infection or onward spread especially as vaccine-induced immunity began to wane. This combination of high viral load, rapid global expansion, heterogeneous community spread, and partial vaccine breakthrough firmly established Delta as a pivotal variant in shaping the pandemic's trajectory prior to the emergence of Omicron.




Figure 3: Global Transmission Patterns — Delta Variant (B.1.617.2)

Delta Preventative Strategies

The emergence of the Delta variant marked a decisive shift in global public health strategy, necessitating a return to more intensive and adaptive prevention approaches. Given Delta's significantly higher transmissibility, shorter generation time, and increased viral load compared to earlier strains, single-intervention approaches proved insufficient to contain its spread. An effective response therefore required a multi-pronged framework that combined accelerated vaccination with reinforced non-pharmaceutical interventions (NPIs).

The intensification of vaccination campaigns represented the most critical preventative strategy during the Delta wave. Although vaccine effectiveness against infection declined over time and with fewer doses, vaccines remained highly protective against severe disease, hospitalization, and death. This evidence prompted the widespread implementation of booster dose programs designed to restore waning immunity and improve population-level protection. Moreover, the elevated basic reproduction number of Delta demanded higher vaccination coverage thresholds to meaningfully reduce transmission, reinforcing the urgency of equitable and accelerated vaccine distribution, particularly in low- and middle-income countries where vaccine access remained constrained (Kumar et al., 2022).

Healthcare interventions varied significantly across countries in response to the Delta variant. The United Kingdom implemented a “Freedom Day” on 19 July 2021, which lifted most legal restrictions despite rising Delta cases, hence relying on vaccination coverage as the primary mitigation strategy (Meyerowitz and Richterman 271). On the contrary, Australia adopted strict elimination strategies such as prolonged lockdowns and state broader closures (Murray et al. 3). Other countries such as Indonesia and India, each facing severe healthcare system strain, significantly struggled with hospital overcapacity and oxygen shortages. This highlights how resource availability shaped the nature and effectiveness of interventions across different healthcare settings (Dhar et al. 997).

In parallel, non-pharmaceutical interventions regained prominence as essential tools for transmission reduction. Public health agencies, including the Centers for Disease Control and Prevention (CDC), revised their earlier relaxed guidance and reinstated mask mandates even for fully vaccinated individuals, particularly in indoor and high-transmission settings. Physical distancing, improved ventilation, limits on large gatherings, and enhanced testing capacity were similarly emphasized as necessary complements to vaccination. Critically, evidence consistently showed that NPIs were most effective when implemented in combination and early in the course of a surge, rather than reactively once transmission was already widespread (Murray et al., 2024). The Delta experience ultimately demonstrated that effective pandemic control requires the sustained integration of vaccination and behavioral interventions, and it established a more flexible and layered public health framework to guide responses to subsequent variants of concern.

OMICRON

The Omicron variant (B.1.1.529) was first identified in South Africa in late November 2021 and rapidly emerged as the most significant evolutionary departure from the original SARS-CoV-2 strain. It carries over 30 mutations in the spike protein alone, with a particularly high concentration in the receptor-binding domain (RBD) and the N-terminal domain (NTD). The RBD is the portion of the spike protein responsible for binding to human ACE2 receptors and facilitating viral entry into host cells, while the NTD plays an important role in viral structure and immune recognition, often serving as an antibody binding site. The sheer density and distribution of these mutations substantially altered Omicron's antigenic profile, enabling enhanced receptor binding and dramatically reduced neutralization by antibodies generated through prior vaccination or infection (Zhang et al., 2022; Roy, 2024).

Compared to Delta, Omicron's clinical profile shifted markedly toward upper respiratory tract involvement, with infection predominantly affecting the nasal passages, throat, and upper airways rather than the lungs. This anatomical shift contributed to a lower risk of severe pneumonia and reduced rates of hospitalization and death relative to prior variants, particularly among vaccinated individuals. Common symptoms of Omicron infection include sore throat, runny nose, persistent cough, fever, fatigue, headaches, and muscle aches—a profile more closely resembling influenza than the severe respiratory failure associated with earlier pandemic waves. However, Omicron's lower individual severity was substantially offset by its extraordinary transmissibility, which produced very large absolute numbers of hospitalizations and deaths globally, particularly among unvaccinated, elderly, and immunocompromised populations (Lundberg et al., 2022).

Understanding Global Transmission Patterns of Omicron Virus

Omicron's global dominance was achieved with remarkable speed. While Delta took 56 days to become dominant across 12 locations, Omicron achieved dominance within approximately 28 days—nearly twice as fast—illustrating the degree to which its transmissibility surpassed that of prior variants (Murray et al., 2024). This rapid ascent was facilitated by Omicron's exceptional immune evasion capacity, which rendered large proportions of previously immune individuals—whether through vaccination or prior infection—susceptible to reinfection. The result was the largest wave of COVID-19 cases observed during the pandemic across most global regions.

Analysis of overlapping Delta and Omicron outbreaks during the transition period in late 2021 and early 2022 confirmed that Omicron's rise did not proportionally translate into equivalent increases in mortality, reflecting its relatively reduced intrinsic severity. However, the sheer scale of infection produced by Omicron meant that even small rates of severe disease translated into significant healthcare system strain in many settings (Lundberg et al., 2022).

Beyond the initial BA.1 subvariant, Omicron has continued to evolve through a succession of sublineages, each demonstrating staggered yet rapid continental spread. BA.1 initially displaced Delta and achieved near-complete dominance in Europe by mid-2022, followed by BA.2, BA.4, and BA.5, the last of which became the globally dominant strain by late 2022 due to increased transmissibility and enhanced immune escape from BA.1-induced immunity. Subsequent subvariants, including XBB.1.5 and BQ.1.1, extended the evolutionary trajectory further, spreading rapidly as a result of compounded immune evasion mutations (Roy, 2024).

The most recent sublineages have maintained this trend of accelerated spread and heightened immune escape. By 2025, multiple Omicron-descended sublineages had emerged as dominant global strains. NB.1.8.1, characterized by spike protein mutations that further enhance receptor binding and immune evasion, had spread across 22 countries and accounted for over 10% of global sequences. LP.8.1 had risen to account for approximately 38% of global sequences, while XEC demonstrated substantial prevalence in

countries including the United States and the United Kingdom (Meyerowitz & Richterman, 2022). This progressive pattern—whereby newer subvariants consistently spread faster, achieve greater global dominance, and evade prior immunity more effectively—has profoundly strained global surveillance and response systems, resulting in repeated surges that have complicated efforts to achieve sustained pandemic control.




Figure 4: Global Transmission Patterns — Omicron Variant (B.1.1.529)

Omicron Preventative Strategies

The emergence of the Omicron variant signaled a fundamental shift in the management of the COVID-19 pandemic, requiring public health strategies to adapt rapidly to an unprecedented combination of extreme transmissibility and profound immune evasion. Unlike the Delta wave, during which intensified containment could meaningfully limit spread within defined populations, Omicron's shortened doubling time and immune escape capacity rendered traditional containment-focused approaches largely insufficient. This compelled public health authorities globally to pivot toward longer-term, adaptive management frameworks oriented around mitigating severe outcomes rather than preventing infection entirely.

The reconfiguration of vaccination policy was among the most consequential strategic responses to Omicron. Existing two-dose vaccine regimens, which had offered substantial protection against Delta, demonstrated sharply reduced effectiveness against Omicron infection, particularly with respect to preventing symptomatic disease. Despite this reduced effectiveness against infection, vaccines retained meaningful protection against severe illness, hospitalization, and death, especially following booster

administration. This evidence prompted the rapid expansion of booster programs, including third and fourth doses for vulnerable populations such as the elderly and immunocompromised, and accelerated the development and deployment of Omicron-specific bivalent vaccines designed to more closely match circulating strains. Maintaining high vaccination coverage therefore remained essential for mitigating large-scale outbreaks and reducing pressure on healthcare systems (Zhang et al., 2022).

Country-level responses to Omicron varied considerably across nations. South Africa, where Omicron was first detected, evidently avoided reimposing strict lockdowns based on findings of reduced severity and high prior infection rates in the population (Viana et al. 681). Denmark became one of the first countries to lift all Covid-19 restrictions in February 2022. This signalled a shift toward endemic management (Lundberg et al. 4). Other countries such as the United States accelerated its bivalent booster rollout, while China maintained its strict Zero-Covid policy in 2022 before abruptly lifting restrictions in December of that year, causing a surge in cases (Murray et al. 4).

Non-pharmaceutical interventions (NPIs) remained important components of the public health response to Omicron, though their application required re-evaluation in light of the variant's distinct epidemiological characteristics. Mask wearing, physical distancing, enhanced ventilation, and hand hygiene continued to be reinforced by organizations such as the World Health Organization as complementary measures to vaccination. However, Omicron's short generation time—estimated at approximately two to three days—significantly undermined the effectiveness of test-trace-isolate strategies, which depend on identifying and quarantining contacts before they become infectious. This limitation highlighted the inadequacy of relying on traditional containment methods in isolation and reinforced the need for layered, multicomponent interventions (Murray et al., 2024).

The Omicron wave accelerated a broader strategic transition in pandemic management—from an acute containment model to a sustainable endemic management model. This shift involved recalibrating risk thresholds, adjusting isolation and testing guidance to balance public health goals with social and economic sustainability, and strengthening healthcare system resilience to manage recurring surges. The lessons drawn from both the Delta and Omicron waves have collectively underscored that effective responses to rapidly evolving pathogens require standing infrastructure for genomic surveillance, flexible policy frameworks capable of rapid adjustment, and equitable access to vaccines and therapeutics across all global populations.

CONCLUSION

The emergence of the Delta and Omicron variants represented two of the most consequential turning points in the COVID-19 pandemic, each fundamentally reshaping how governments, healthcare systems, and public health authorities understood and responded to SARS-CoV-2. The evidence presented in this paper demonstrates that while both variants were characterised by significantly elevated transmissibility relative to earlier strains, they diverged considerably in their clinical profiles, immune evasion

mechanisms, and downstream public health consequences. Delta was associated with increased hospitalisation, ICU admission, and mortality, particularly among unvaccinated populations, and its shorter generation time and higher viral loads rendered conventional containment strategies substantially less effective. Omicron, by contrast, produced comparatively milder disease in vaccinated individuals but spread at an unprecedented pace, evaded prior immunity more extensively, and ultimately generated the largest wave of infections observed throughout the pandemic. Critically, the sheer volume of Omicron infections meant that even a reduced rate of severe outcomes translated into significant pressure on healthcare systems worldwide.

Together, these variants exposed deep structural vulnerabilities in global pandemic preparedness, including gaps in genomic surveillance capacity, inequitable access to vaccines and therapeutics, and the limitations of reactive rather than anticipatory public health frameworks. The repeated need to revise guidance, reinstate non-pharmaceutical interventions, and rapidly reformulate vaccines illustrated that static, one-size-fits-all approaches are inadequate in the face of a rapidly evolving pathogen. Effective responses consistently required the early and simultaneous deployment of multiple interventions rather than reliance on any single measure.

Despite advances in genomic surveillance during the pandemic, significant gaps remained in the global monitoring of Covid variants. Low- and middle-income countries faced considerable limitations in sequencing capacity. This meant that variants like Delta and Omicron were often detected and characterised by wealthier nations before adequate data existed from the regions that were most severely affected (Roy 8). This inequity in surveillance infrastructure caused delays in understanding accurate transmission dynamics, which hampers the timeliness of international public health responses (Banerjee et al. 6). Moreover, the reliance on reported case data underestimated actual infection rates in settings with limited testing access, which skewed the global picture of variant spread (Murray et al. 5).

The emergence of both the Delta and Omicron variants highlights the need for strengthened global surveillance systems that are capable of detecting and characterising novel variants efficiently and equitably. Efforts such as investing in genomic sequencing infrastructure across all nations and coordinating through bodies like the WHO and GISAID are essential to ensure that future variants are identified at the source instead of after widespread dissemination has occurred. Additionally, the trends of Delta and Omicron highlight the importance of maintaining flexible and adaptable public health frameworks, especially the ones that are capable of quickly shifting between containment and mitigation strategies as new evidence emerges (Fisman and Tuite). Ultimately, the lessons of these two variants reinforce that pandemic preparedness must be a continuous and globally coordinated effort.

The broader lessons of this analysis carry significant implications for future pandemic readiness. Governments and international health bodies should prioritise sustained investment in genomic sequencing infrastructure to enable early variant detection and accelerate response timelines. Equitable global vaccine distribution must be treated as a strategic imperative rather than an aspirational goal, as unequal access not only leaves populations vulnerable but also creates conditions conducive to the

emergence of new variants of concern. Healthcare systems require structural reinforcement to absorb surge capacity without compromising routine care, and this resilience must be built during inter-pandemic periods rather than assembled under crisis conditions.

Looking ahead, several important research directions remain. The long-term health consequences of SARS-CoV-2 infection, including Post-acute sequelae of COVID-19 (Long Covid), warrant continued investigation, particularly as the cumulative burden of repeated infections grows across populations. Research into how immunity evolves following multiple infections or booster doses will be essential for guiding future vaccination policy. Additionally, the integration of artificial intelligence and predictive epidemiological modelling into early warning systems holds considerable promise for improving outbreak detection and enabling more proactive public health responses. Addressing these questions will be critical to building adaptive, resilient health systems capable of responding effectively to future global health threats.

REFERENCES

- Ada Health. "COVID-19 Omicron Variant Symptoms." Ada Health, n.d., ada.com/covid/covid-19-omicron-variant-symptoms/.
- Ada Health. "COVID-19 Symptoms: Delta Variant." Ada Health, n.d., ada.com/covid/covid-19-symptoms-delta-variant/.
- Andrews, Nick, et al. "COVID-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant." *New England Journal of Medicine*, vol. 386, no. 16, 2022, pp. 1532–1546, doi.org/10.1056/NEJMoa2119451.
- Banerjee, A., et al. "SARS-CoV-2 Variants and Immune Escape Mechanisms." *Zoonoses*, 2021, doi.org/10.15212/ZOONOSSES-2021-0005.
- Callaway, Ewen. "Omicron Likely to Weaken COVID Vaccine Protection." *Nature*, 2021, www.nature.com/articles/d41586-021-03672-3.
- Centers for Disease Control and Prevention. "CDC Updates and Shortens Recommended Isolation and Quarantine Period for General Population." CDC, 27 Dec. 2021, www.cdc.gov/media/releases/2021/s1227-isolation-quarantine-guidance.html.
- Centers for Disease Control and Prevention. "Science Brief: Omicron (B.1.1.529) Variant." CDC, 2022, www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-omicron-variant.html.
- Dhar, M. S., et al. "Genomic Characterization and Epidemiology of an Emerging SARS-CoV-2 Variant in Delhi, India." *Science*, vol. 374, no. 6570, 2021, pp. 995–999, doi.org/10.1126/science.abj9932.
- Fisman, David N., and Ashleigh R. Tuite. "Evaluation of the Relative Virulence of Novel SARS-CoV-2 Variants: A Retrospective Cohort Study in Ontario, Canada." *CMAJ*, vol. 193, no. 42, 2021, pp. E1619–E1625, doi.org/10.1503/cmaj.211248.

- GISAID Initiative. "SARS-CoV-2 Variant Tracking." GISAID, 2021, gisaid.org/.
- He, J., et al. "Global Transmission Dynamics of the Delta Variant." *Nature Communications*, vol. 13, 2022, doi.org/10.1038/s41467-022-28506-2.
- Kumar, S., et al. "Omicron and Delta Variant of SARS-CoV-2: A Comparative Computational Study of Spike Protein." *Journal of Medical Virology*, vol. 94, no. 4, 2022, pp. 1641–1649, doi.org/10.1002/jmv.27526.
- Lundberg, A. L., et al. "Overlapping Delta and Omicron Outbreaks during the COVID-19 Pandemic." *JAMA Network Open*, 2022, doi.org/10.1001/jamanetworkopen.2022.34909.
- MD Anderson Cancer Center. "COVID-19 New Delta Variant: What You Need to Know." MD Anderson Cancer Center, 2021, www.mdanderson.org/cancerwise/covid-19-new-delta-variant--what-you-need-to-know.h00-159461634.html.
- Meyerowitz, Eric A., and Aaron Richterman. "SARS-CoV-2 Transmission and Prevention in the Era of the Delta Variant." *Infectious Disease Clinics of North America*, vol. 36, no. 2, 2022, pp. 267–293.
- Mlcochova, Petra, et al. "SARS-CoV-2 B.1.617.2 Delta Variant Replication and Immune Evasion." *Nature*, vol. 599, no. 7883, 2021, pp. 114–119, doi.org/10.1038/s41586-021-03944-y.
- Murray, J. M., et al. "SARS-CoV-2 Delta and Omicron Community Transmission." *Epidemics*, 2024, doi.org/10.1016/j.epidem.2024.100757.
- National Cancer Institute. "SARS-CoV-2." NCI Dictionary of Cancer Terms, n.d., www.cancer.gov/publications/dictionaries/cancer-terms/def/sars-cov-2.
- News Medical. "What Is a Receptor-Binding Domain (RBD)?" News-Medical.Net, 2022, [www.news-medical.net/health/What-is-a-Receptor-Binding-Domain-\(RBD\).aspx](https://www.news-medical.net/health/What-is-a-Receptor-Binding-Domain-(RBD).aspx).
- Our World in Data. "Coronavirus (COVID-19) Cases." Our World in Data, 2022, ourworldindata.org/covid-cases.
- Roy, S. "COVID-19 Variants: A Review of the Evolution of the SARS-CoV-2 Genome." *Frontiers in Microbiology*, vol. 15, 2024, article 1456424, doi.org/10.3389/fmicb.2024.1456424.
- Viana, R., et al. "Rapid Epidemic Expansion of the SARS-CoV-2 Omicron Variant in Southern Africa." *Nature*, vol. 603, no. 7902, 2022, pp. 679–686, doi.org/10.1038/s41586-022-04411-y.
- World Health Organization. "Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern." WHO, 26 Nov. 2021, [www.who.int/news/item/26-11-2021-classification-of-omicron-\(b.1.1.529\)-sars-cov-2-variant-of-concern](https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern)?
- World Health Organization. "Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States." WHO, 2021, [www.who.int/publications/m/item/enhancing-readiness-for-omicron-\(b.1.1.529\)-technical-brief-and-priority-actions-for-member-states](https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states)?

- World Health Organization. "Statement on the Fifteenth Meeting of the IHR Emergency Committee on the COVID-19 Pandemic." WHO, 5 May 2023, [www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-\(2005\)-emergency-committee-regarding-the-coronavirus-disease-\(covid-19\)-pandemic?](http://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic?)
- World Health Organization. "Tracking SARS-CoV-2 Variants." WHO, n.d., www.who.int/activities/tracking-SARS-CoV-2-variants?
- World Health Organization. "Weekly Epidemiological Update on COVID-19 — 31 August 2021." WHO, 31 Aug. 2021, www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---31-august-2021?
- World Health Organization. "WHO Coronavirus (COVID-19) Dashboard." WHO, 2022, covid19.who.int/?
- Zhang, X., et al. "Immune Evasion of SARS-CoV-2 Omicron Variant from mRNA-Based Vaccine-Stimulated Neutralizing Antibodies." *Cell Reports Medicine*, vol. 3, no. 6, 2022, article 100654, doi.org/10.1016/j.xcrm.2022.100654.